Abstract: The present invention relates to the treatment and prevention of cancers, particularly cancers whose growth is reduced or inhibited by immunostimulatory therapy, by the administration of interleukin-17D (IL-17D), compounds that can increase the production, half-life, or activity of IL-17D, or compositions that contain IL-17D.

Abstract: Provided are antibodies, including functional antibody fragments, that specifically bind to discoidin domain receptors (DDRs), and in particular to DDR1 proteins, as well as uses and method of using such antibodies, including in the detection, diagnosis and treatment of diseases and conditions associated with DDR1.

Abstract: Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: The invention concerns a pharmaceutical composition comprising, as the active ingredient, human natural antibodies of the IgG isotype, that neutralize the activity of a human cytokine selected from VEGF, IFN?, IL-4, TNF? and TGF?, the said neutralizing antibodies inhibiting at least 50% of the maximum biological activity induced by an amount ranging from 0.006 ng to 0.05 ng of the said cytokine in vitro.

Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.

Abstract: The invention provides compositions and methods to form pores in situ within hydrogels following hydrogel injection. Pores formed in situ via degradation of sacrificial porogens within the surrounding hydrogel facilitate recruitment or release of cells. Disclosed herein is a material that is not initially porous, but which becomes macroporous over time.

Abstract: Provided are methods for characterizing microvesicles or other membranous structures. The methods involve assaying samples for microvesicles or other membranous structures, and include in certain aspects determining the presence or absence of tissue transglutaminase (tTG) and/or cross-linked fibronection (FN). The microvesicles or other membranous structures can be separated from a sample using recombinant tTG or a derivative of it, or tTG or FN binding partners. Also provided are methods for inhibiting the transfer of cargo from microvesicles which contain tTG to one or more cells. This involves administering to the individual a tTG inhibitor, such as a cell-impermeable tTG inhibitor. Also provided are compositions which contain a population of microvesicles or other membranous structures, where the population is attached to tTG or a derivative thereof, or to tTG or an FN binding partner. Kits which contain reagents and other components for carrying out the method are also provided.

Abstract: The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LT?R signaling are also provided.

Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.

Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.

Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.

Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.

Abstract: The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.

Abstract: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e.g. inhibition of MCP-1 and/or MIP-1?) to treat or prevent chronic pelvic pain syndrome.

Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

Abstract: A method of treating or preventing inflammatory related diseases in a subject in need thereof comprising administering to said subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is provided. A method for inhibiting cancer metastasis or growth of tumor in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is also provided.

Abstract: The invention relates to a method of treating rheumatoid arthritis in a patient comprising the steps of: a) providing a biological sample from a patient, b) measuring the level of soluble VE-cadherin in the biological sample obtained at step a); c) comparing said level of soluble VE-cadherin with a predetermined reference value, and if the level of soluble VE-cadherin measured at step b) is higher that the predetermined reference value, treating the patient until a basal level of soluble VE-cadherin is reached.

Abstract: Silent brain ischemia (SBI) or ischemia of other organs can result from an embolism that is introduced into the arterial system during a medical procedure. The application provides a method of administering a FXII inhibitor in a patient receiving a medical procedure and animal models useful for studying ischemia including SBI and ischemia in other organs, and for evaluating candidate therapeutics.

Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.

Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.

Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.

Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.

Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

Abstract: The present invention relates to methods and medicaments useful for the treatment of brain tumors by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods and medicaments are provided for reducing tumor cell proliferation and tumor growth, reducing tumor vascularity, inhibiting tumor cell invasion, improving tumor surgical margins and prolonging survival of patients with brain tumors.

Abstract: In certain embodiments, the present invention provides a method of treating an IP10-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IPIO antibody; (b) detecting the level of the anti-IPIO antibody in a sample of the subject; and (c) if the level of the anti-IPIO antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IPIO antibody in the subject such that the IP-10 related disease in the subject is treated.

Abstract: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.

Abstract: The present invention provides a fully human anti-VEGF monoclonal antibody, the preparation method and use thereof. The fully human anti-VEGF monoclonal antibody is obtained by using antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used to prepare anti-tumor medicines.

Abstract: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of neutrophils and complications arising therefrom. The present invention further provides agents and pharmaceutical compositions comprising agents which inhibit the activity of G-CSF or its receptor, interfere with G-CSF signaling and/or which down-regulate expression of G-CSF or its receptor.

Abstract: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.

Abstract: To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.

Abstract: Methods of promoting wound healing in a subject is disclosed. The method include applying a Granzyme B (Granzyme B) inhibitor to the wound. The wound may be a skin wound. The Granzyme B inhibitor may be comprised of nucleic acids, or peptides, including but not limited to antibodies, or small molecules.

Abstract: This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided.

Abstract: Provided are a pharmaceutical composition which enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, wherein the cancer has resistance to the molecular target drug, and a cancer therapeutic agent effective against a cancer having resistance to a molecular target drug, such as gefitinib and erlotinib. The pharmaceutical composition comprising an HGF-MET receptor pathway inhibitor enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, even though the cancer has resistance to the molecular target drug. The cancer therapeutic agent comprising a molecular target drug in combination with an HGF-MET receptor pathway inhibitor is effective against a cancer having resistance to the molecular target drug.

Abstract: The disclosure relates to methods for treating a sclerostin-expressing cancer, e.g., a squamous cell carcinoma (SCC), e.g., SCC of the upper aerodigestive tract, esophagus, or lung, employing a therapeutically effective amount of at least one sclerostin antagonist, e.g., an anti-sclerostin antibody, such as Antibody 1, 2, 3, 4 or 5.

Abstract: The present invention relates to IL-25 antibody VH domains and target binding members (e.g., antibodies) that comprise such antibody VH domains and bind IL-25. The invention also relates to compositions comprising target binding members {e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).

Abstract: Provided are methods of treating tissue fibrosis comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a hyaluron synthase (HAS) or CD44. Further provided are methods of inhibiting myofibroblast invasion, or of reducing matrix deposition in the lung, the methods comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a HAS or CD44. Further provided are methods of determining the progression of pulmonary fibrosis, the methods comprising determining the level of matrix metalloproteinase expression in a cell, and comparing the level of expression to that of a control cell, wherein an increased level of expression relative to the control cell indicates progression of the disease.

Abstract: Methods and compositions for modulating cyclophilin D, e.g., at least one cyclophilin D biological activity, are provided. Modulation of cyclophilin D is useful in preventing or treating obesity, an overweight condition, or in accommodating a desire to lose weight as well as being useful in treating a variety of kidney diseases.

Abstract: Anti-TACE (ADAM17) antibodies are disclosed that for the first time in the art are capable of binding to TACE, of acting as antagonists of one or more its biological activities, in particular by binding to TACE in a cross domain binding mode in which residues in both the catalytic domain and in the cysteine rich/disintegrin domains (Dis-Cys) are involved in antibody binding to TACE, helping to improve the specificity of the antibody binding and/or helping to improve inhibition of TACE biological activity. The therapeutic uses of the antibodies, in particular for the treatment of cancer are disclosed.

Abstract: The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.

Abstract: Methods and pharmaceutical compositions for treating severe ischemic events including cerebral infarction, cardiac infarction, or pulmonary embolism, comprising a thrombolytic intervention including thrombolytic agents and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are disclosed.

Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, for monitoring the effectiveness of treatment of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, and for drug development.

Abstract: The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease.

Abstract: The present invention generally relates to the technical field of medicine, in particular to the field of neurodegenerative, neurological and protein misfolding disorders such as amyloidosis. By establishing a role of ankG in APP processing the method of the present invention provides a new insight into the role of ankG in AD pathology and provides ankG as a target, drug, diagnostic agent and particularly as a vaccine in the treatment and diagnosis of the pathogenesis of Alzheimer's disease (AD).

Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.